Optimized patient selection in high-risk protected percutaneous coronary intervention

被引:9
作者
Leick, Juergen [1 ]
Werner, Nikos [1 ]
Mangner, Norman [2 ]
Panoulas, Vasileios [3 ,4 ,5 ]
Aurigemma, Cristina [6 ]
机构
[1] Barmherzige Bruder Hosp, Heart Ctr Trier, Dept Cardiol, Nordallee 1, D-54296 Trier, Germany
[2] Tech Univ Dresden, Dept Internal Med & Cardiol, Herzzentrum Dresden, Dresden, Germany
[3] Guys & St Thomas NHS Fdn Trust, Harefield Hosp, Royal Brompton Hosp, Dept Cardiol, London UB9 6BJ, England
[4] Guys & St Thomas NHS Fdn Trust, Harefield Hosp, Dept Cardiol, London UB9 6BJ, England
[5] Imperial Coll London, Natl Heart & Lung Inst, Cardiovasc Sci, London, England
[6] Fdn Policlin Univ A Gemelli IRCCS, Inst Cardiol, I-00168 Rome, Italy
关键词
Protected PCI; High-risk PCI; Left-ventricular function; Mechanical circulatory support; Comorbidities; Haemodynamic support; MECHANICAL CIRCULATORY SUPPORT; VENTRICULAR ASSIST DEVICE; INTRAAORTIC BALLOON PUMP; UNPROTECTED LEFT MAIN; HEMODYNAMIC SUPPORT; ARTERY-DISEASE; IMPELLA; 2.5; CLINICAL-TRIAL; REAL-WORLD; REVASCULARIZATION;
D O I
10.1093/eurheartjsupp/suac060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Percutaneous mechanical circulatory support (pMCS) is increasingly used in patients with poor left-ventricular (LV) function undergoing elective high-risk percutaneous coronary interventions (HR-PCIs). These patients are often in critical condition and not suitable candidates for coronary artery bypass graft surgery. For the definition of HR-PCI, there is a growing consensus that multiple factors must be considered to define the complexity of PCI. These include haemodynamic status, left-ventricular ejection fraction, clinical characteristics, and concomitant diseases, as well as the complexity of the coronary anatomy/lesions. Although haemodynamic support by percutaneous LV assist devices is commonly adopted in HR-PCI (protected PCI), there are no clear guideline recommendations for indication due to limited published data. Therefore, decisions to use a nonsurgical, minimally invasive procedure in HR-PCI patients should be based on a risk-benefit assessment by a multidisciplinary team. Here, the current evidence and indications for protected PCI will be discussed.
引用
收藏
页码:J4 / J10
页数:7
相关论文
共 47 条
  • [1] AbdelWahab M., 2018, CIRC-CARDIOVASC INTE, V11, P1
  • [2] Impact of left-ventricular end-diastolic pressure as a predictor of periprocedural hemodynamic deterioration in patients undergoing Impella supported high-risk percutaneous coronary interventions
    Al-Rashid, Fadi
    Mahabadi, Amir A.
    Johannsen, Laura
    Soldat, Julian
    Dykun, Iryna
    Janosi, Rolf Alexander
    Totzeck, Matthias
    Rassaf, Tienush
    [J]. IJC HEART & VASCULATURE, 2020, 26
  • [3] New-generation mechanical circulatory support during high-risk PCI: a cross-sectional analysis
    Ameloot, Koen
    Bastos, Marcello
    Daemen, Joost
    Schreuder, Jan
    Boersma, Eric
    Zijlstra, Felix
    Van Mieghem, Nicolas M.
    [J]. EUROINTERVENTION, 2019, 15 (05) : 427 - 433
  • [4] The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support
    Amin, Amit P.
    Spertus, John A.
    Curtis, Jeptha P.
    Desai, Nihar
    Masoudi, Frederick A.
    Bach, Richard G.
    McNeely, Christian
    Al-Badarin, Firas
    House, John A.
    Kulkarni, Hemant
    Rao, Sunil, V
    [J]. CIRCULATION, 2020, 141 (04) : 273 - 284
  • [5] A Practical Approach to Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention An Interventional Perspective
    Atkinson, Tamara M.
    Ohman, E. Magnus
    O'Neill, William W.
    Rab, Tanveer
    Cigarroa, Joaquin E.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (09) : 871 - 883
  • [6] Clinical Impact of Revascularization Extent in Patients Undergoing Impella-Protected PCI Enrolled in a Nationwide Registry
    Aurigemma, Cristina
    Buzotta, Francesco
    Chieffo, Alaide
    Briguori, Carlo
    Piva, Tommaso
    De Marco, Federico
    Di Biasi, Maurizio
    Pagnotta, Paolo
    Casu, Gavino
    Garbo, Roberto
    Trani, Carlo
    Tarantini, Giuseppe
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (06) : 717 - 719
  • [7] Six months follow-up of protected high-risk percutaneous coronary intervention with the microaxial Impella pump: results from the German Impella registry
    Baumann, Stefan
    Werner, Nikos
    Al-Rashid, Fadi
    Schaefer, Andreas
    Bauer, Timm
    Sotoudeh, Ramin
    Bojara, Waldemar
    Shamekhi, Jasmin
    Sinning, Jan-Malte
    Becher, Tobias
    Eder, Frederik
    Akin, Ibrahim
    [J]. CORONARY ARTERY DISEASE, 2020, 31 (03) : 237 - 242
  • [8] Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial ImpellaA® pump: results from the German ImpellaA® registry
    Baumann, Stefan
    Werner, Nikos
    Ibrahim, Karim
    Westenfeld, Ralf
    Al-Rashid, Fadi
    Sinning, Jan-Malte
    Westermann, Dirk
    Schaefer, Andreas
    Karatolios, Konstantinos
    Bauer, Timm
    Becher, Tobias
    Akin, Ibrahim
    [J]. CLINICAL RESEARCH IN CARDIOLOGY, 2018, 107 (08) : 653 - 657
  • [9] Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device
    Becher, Tobias
    Baumann, Stefan
    Eder, Frederik
    Perschka, Simon
    Lossnitzer, Dirk
    Fastner, Christian
    Behnes, Michael
    Doesch, Christina
    Borggrefe, Martin
    Akin, Ibrahim
    [J]. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2019, 8 (04) : 360 - 368
  • [10] Brener SJ, 2021, J INVASIVE CARDIOL, V33, pE253